Differential Diagnostics of Etiology of Acute Infections
1 other identifier
observational
169
0 countries
N/A
Brief Summary
Method for diagnostics of the origin of infections (bacterial vs viral) based on the identification of activation markers of blood neutrophils and monocytes will be developed.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2017
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 3, 2017
CompletedFirst Submitted
Initial submission to the registry
May 17, 2017
CompletedFirst Posted
Study publicly available on registry
May 22, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 10, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
December 29, 2018
CompletedJanuary 9, 2019
January 1, 2019
1.9 years
May 17, 2017
January 7, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Sensitivity of the diagnosis of bacterial vs viral acute infection
Sensitivity of the diagnosis of bacterial vs viral acute infection using proposed method
1 month
Specificity of the diagnosis of bacterial vs viral acute infection
Specificity of the diagnosis of bacterial vs viral acute infection using proposed method
1 month
Study Arms (3)
Neuroinfections
Patients with acute neuroinfections of bacterial and viral ethology.
Intestinal Infectious Diseases
Patients with acute intestinal infectious diseases of bacterial and viral ethology.
Control group
Control group of healthy persons
Eligibility Criteria
Patients admitted to the infectious departments of city hospitals.
You may qualify if:
- neuroinfections or acute intestinal infections;
- the possibility of blood sampling within a period of up to 24 hours from the moment of admission to hospital;
- less than 72 hours passed after the onset of the disease and until blood was collected;
You may not qualify if:
- refuse of patient to participate in the trial;
- more than 24 hours passed after the patient entered the hospital;
- the disease began more than 72 hours ago;
- concomitant severe acute and chronic diseases;
- malignant neoplasms, treatment at a time of less than 1 year, autoimmune diseases in the phase of exacerbation;
- pregnancy/lactation;
- HIV, Hepatites B/C;
- active tuberculosis;
- alcohol use disorder/drug addiction.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Biospecimen
Whole blood
Study Officials
- STUDY DIRECTOR
Andrei Y Hancharou, Dr
Head of the Laboratory for Immunology and Cellular Biotechnology, The Republican Research and Practical Center for Epidemiology and Microbiology
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Head of the Laboratory for Immunology and Cellular Biotechnology,
Study Record Dates
First Submitted
May 17, 2017
First Posted
May 22, 2017
Study Start
January 3, 2017
Primary Completion
December 10, 2018
Study Completion
December 29, 2018
Last Updated
January 9, 2019
Record last verified: 2019-01
Data Sharing
- IPD Sharing
- Will not share